An antibody to a protein on blood-forming stem cells may allow bone marrow transplants without the need for chemotherapy and radiation, according to a Stanford study.
February 11, 2019 - By Krista Conger
An antibody-based treatment can gently and effectively eliminate diseased blood-forming stem cells in the bone marrow to prepare for the transplantation of healthy stem cells, according to a study in mice by researchers at the Stanford University School of Medicine.
The researchers believe the treatment could circumvent the need to use harsh, potentially life-threatening chemotherapy or radiation to prepare people for transplant, vastly expanding the number of people who could benefit from the procedure.
“There are many blood and immune disorders that could be cured by a transplant of healthy stem cells,” said Judith Shizuru, MD, PhD, professor of medicine at Stanford. “But the pre-treatments necessary to get the healthy cells to transplant effectively are so toxic that we can’t offer this option to many patients. A treatment that specifically targets only blood-forming stem cells would allow us to potentially cure people with diseases as varied as sickle cell disease, thalassemia, autoimmune disorders and other blood disorders.”
Shizuru is the senior author of the study, which will be published online Feb. 11 in Blood. Postdoctoral scholar Wendy Pang, MD, PhD, and assistant professor of pediatrics Agnieszka Czechowicz, MD, PhD, share lead authorship of the work.
The study is one of two recently co-authored by Shizuru, Czechowicz and research associate Hye-Sook Kwon, PhD, indicating that an antibody targeting a protein called CD117 on the surface of blood-forming, or hematopoietic, stem cells can efficiently and safely eliminate the cells in mice and non-human primates. CD117 is a protein found on the surface of the stem cells. It regulates their growth and activity; the antibody, called SR1, binds to the protein and prevents its function.
The use of antibodies against CD117 to eliminate blood-forming stem cells is based on studies conducted in the laboratory of study co-author Irving Weissman, MD, director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine and of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford, and by then-graduate student Czechowicz.
Ongoing clinical trial
The results of these studies, including a recently published article in Bloodco-authored by Kwon that showed the antibody treatment was safe in non-human primates, set the stage for a clinical trial of the antibody at Stanford and the University of California-San Francisco in children with an immune disorder called severe combined immunodeficiency.
Hematopoietic stem cells are found in the bone marrow. They give rise to all the cells of the blood and immune system. Blood cancers, such as leukemia, arise when the stem cells or their progeny begin dividing uncontrollably; other genetic conditions such as sickle cell anemia or thalassemia occur when the hematopoietic stem cells generate malformed red blood cells or hemoglobin.
Often the best chance for a cure for these and other diseases originating in the bone marrow is to eliminate the patient’s own defective hematopoietic stem cells and replace them with healthy stem cells from a closely matched donor. But in order to do so, the patient must be able to withstand the pre-treatment, known as conditioning. Most conditioning regimens consist of a combination of chemotherapy and radiation in doses high enough to kill stem cells in the marrow.
Shizuru and her colleagues studied a mouse model of a class of human diseases called myelodysplastic syndromes, or MDS. People with MDS are unable to make mature, properly functioning blood cells and the only cure is a stem cell transplant. The disease primarily affects older adults, who are more likely than younger people to have additional, complicating medical factors and who are less likely to withstand the conditioning regimen.
“Many of these people are elderly and unable to qualify for a transplant,” Pang said. “But there is no other cure for MDS.”
We are very hopeful that this body of research is going to have a positive impact on patients by allowing better depletion of diseased cells and engraftment of healthy cells.
Because there are many different types of MDS, the patients are assigned risk levels based on disease type, blood test results and the presence or absence of specific mutations in the affected cells. According to the World Health Organization, patients with low-risk MDS have a median survival rate of 5.5 years; those with high-risk disease have a median survival of 2.2 years.
SR1, the anti-CD117 antibody Pang and Czechowicz studied, recognizes CD117 on the surface of hematopoietic stem cells isolated from either healthy donors or from patients with MDS. They found that the antibody blocked the growth of both healthy and diseased stem cells in a laboratory setting. Then, the researchers investigated the effect of SR1 treatment on mice that were engineered to have a hybrid blood systems consisting of both human and mouse hematopoietic stem cells.
They found in the mice that SR1 quickly and efficiently eliminated both healthy human hematopoietic stem cells and cells isolated from low-risk MDS patients. In those animals with diseased human stem cells, SR1 pre-treatment significantly improved the ability of healthy hematopoietic stem cells to engraft after transplantation.
“SR1 directly targets the disease-initiating cells for elimination in the mice, even though these cells typically have a significant competitive advantage,” Pang said. “This is the first antibody directed against CD117 that has been proven to clear both normal and diseased human cells from the recipient. We are very pleased with the results.”
Although SR1 is also able to significantly reduce the number of high-risk MDS cells from the mice, the researchers found that the effect was transient: The diseased cells eventually returned. However, when anti-CD117 antibody treatment was used in combination with transplants of normal human blood stem cells, normal human blood formation was restored and high-risk MDS cells remained stably suppressed throughout the course of the experiment.
“Based on the results of this study and others, we have received approval from the Food and Drug Administration to move forward with a clinical trial for MDS patients using a version of SR1 appropriate for a trial in humans,” Shizuru said. “We are very hopeful that this body of research is going to have a positive impact on patients by allowing better depletion of diseased cells and engraftment of healthy cells.”
The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
Jessica Poyser, a life science research professional at Stanford and researchers from Memorial Sloan-Kettering Cancer Center, UCSF and the New York University School of Medicine are also co-authors of the study.
Shizuru is a member of the Stanford Institute for Stem Cell and Regenerative Medicine and the Stanford Cancer Institute.
The research was supported by the National Institutes of Health (grants R01CA86065 and R01HL058770), the California Institute for Regenerative Medicine, the Virginia and D.K. Ludwig Fund for Cancer Research, the Gunn/Oliver Research Fund, the HL Snyder Medical Foundation, the Stinehart-Reed Foundation, the Walter V. and Idun Berry Foundation, the Howard Hughes Medical Institute, the Stanford Medical Scholars Research Program and the Paul and Daisy Soros Fellowship for New Americans.
Weissman and Czechowicz are inventors on patents that include the use of anti-CD117 antibodies in hematopoietic stem cell transplant conditioning, and Weissman and Shizuru are inventors on patents that pair anti-CD47 agents and anti-CD117 antibodies for the transplant conditioning. Weissman is a co-founder, stockholder and director of Forty Seven Inc., which has licensed these patents from Stanford University. Shizuru has equity ownership in Forty Seven Inc., and Czechowicz has equity ownership in Forty Seven Inc., Magenta Therapeutics, Beam Therapeutics, Editas Medicines and Global Blood Therapeutics.
Stanford’s Department of Medicine also supported the work.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.